Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

Use of Laser in Rescue AMI
Evolving Utility of Aspirin and Thienopyridines: New Insights Into Anti-Platelet Resistance
Drug-Eluting Stents in AMI: A Proven Strategy?
Low-Molecular Weight Heparins in ACS: New Insights from SYNERGY and STEEPLE
Expanding Use of Bivalirudin Beyond PCI: Lessons from ACUITY to EVOLUTION



ABSORB II Confirms Safety & Efficacy of Bioabsorbable Scaffold

The ABSORB II study, comparing the bioabsorbable everolimus-elluting scaffold with the metallic everolimus-eluting stent, has shown similar acute recoil post implantation but lower acute lumen gain with the bioabsobable scaffold. At 1 year, although angina was lower in the bioabsorbable group, composite device orientated endpoints were similar.

For more, click here





The role of renal denervation in the treatment of resistant hypertension has been under the spot light following the publication of the SYMPLICITY HTN-3 study. The SYMPLICITY-FLEX study undertaken in patients with mild hypertension has failed to show any benefit with renal denervation in reducing blood pressure.




Conflicting Data for Prasugrel in TRANSLATE-ACS

Prasugrel has been an established antiplatelet agent in patients presenting with ACS and treated with PCI. A real-world comparison of prasugrel with clopidogrel in 12,000 ACS patients has shown no differences in the rate of major adverse cardiovascular events.




Security in Lowering the Duration of DAPT

A randomized comparison of 6 months versus 12 months of dual antiplatelet therapy following PCI with second generation DES in low-risk patients has indicated that that the 6 months duration is non-inferior to the 12 months duration. Bleeding and stent thrombosis were similar and numerically very low in both arms of the study.




The End of the Road for PFO Closure in Migraine

There has been much debate regarding the efficacy of PFO closure in relieving migraine symptoms. The PRIMA trial, designed to assess migraine headache frequency at 12 months following PFO closure with the AMPLATZER device, has not show any benefit in patients who had undergone PFIO closure.



Untitled Document
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD
Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY Registry
- Felix Mahfoud, MD
SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months
- George L. Bakris, MD
Aortic Valve-in-Valve: Insights from the Global Registry
- Danny Dvir, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives

A Bioresorbable Everolimus-Eluting Scaffold Versus a Metallic Everolimus-Eluting Stent for Ischaemic Heart Disease Caused by De-Novo Native Coronary Artery Lesions (Absorb Ii): An Interim 1-Year Analysis of Clinical and Procedural Secondary Outcomes From a Randomised Controlled Trial.
P Serruys, et al.
The Lancet 2014 Online
Long-Term Outcome of PCI Versus CABG in Insulin and Non–Insulin-Treated Diabetic Patients - Results from the FREEDOM Trial.
G Dangas, et al.
JACC 2014; 64:1189-1197
Impact of Aortic Valve Calcification, as Measured by MDCT, on Survival in Patients With Aortic StenosisResults of an International Registry Study.
M Clavel, et al.
JACC 2014; 64:1202-1213
Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention: A Contemporary Review.
W Dewilde, et al.
JACC 2014; 64:1270-1280
Improved Quality of Life After 1 Year With an Invasive Versus a Noninvasive Treatment Strategy in Claudicants: One-Year Results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial.
J Nordanstig, et al.
Circ 2014; 130:939-947
Troponin T and B-Type Natriuretic Peptide After On-Pump Cardiac Surgery: Prognostic Impact on 12-Month Mortality and Major Cardiac Events After Adjustment for Postoperative Complications.
G Buse, et al.
Circ 2014; 130:948-957
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011.
H Krumholz, et al.
Circ 2014; 130:966-975
Ivabradine in Stable Coronary Artery Disease Without Clinical Heart Failure.
K Fox, et al.
NEJM 2014; 371:1091-1099
Outcomes 1 Year After Thrombus Aspiration for Myocardial Infarction.
B Lagerqvist, et al.
NEJM 2014; 371:1111-1120
Addressing Barriers to Optimal Oral Anticoagulation Use and Persistence Among Patients With Atrial Fibrillation: Proceedings, Washington, DC, December 3-4, 2012.
P Hess, et al.
AHJ 2014; 168:239-247
Incidence and Correlates of Major Bleeding After Percutaneous Coronary Intervention Across Different Clinical Presentations.
J Loh, et al.
AHJ 2014; 168:249-255
Comparison of Five-Year Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fractions ≤50% Versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2).
A Marui, et al.
AJC 2014; 114:988-996

Poll Archives
Shao-Liang Chen, MD, et al.
| Watch CardioTube Interview
Samir R. Kapadia, MD
| Watch CardioTube Interview
RIBS IV Clinical Trial
Fernando Alfonso MD, PhD
| Watch CardioTube Interview
Gregg W. Stone, MD
| Watch CardioTube Interview
Eric J. Dippel, MD
| Watch CardioTube Interview
Renal artery denervation with a new simultaneous multi-electrode catheter for treatment of resistant hypertension: 12-month update from the first-in-man study
Robert Whitbourn, MD, et al.
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc Analyses of 12-Month Results
Deepak L. Bhatt, MD, MPH, et al.
SYMPLICITY HTN-3: Analysis of the African-American and Non-African American Populations
John M. Flack, MD, et al.
Preclinical Insights Into the Optimal Ablation Location for Renal Denervation Procedures
Robert J. Melder, ScD
Two-Year Clinical Results of OPTIMIZE Trial
Fausto Feres, MD, PhD
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk Patients
Matthew R. Reynolds, MD
Multi-Vessel Versus Single-Vessel Treatment with Resolute Zotarolimus Eluting Stent in the RESOLUTE Global Clinical Program
Ganesh Manoharan, MD
Percutaneous Coronary Intervention of Small Vessels in the RESOLUTE Global Clinical Program: The Impact of Diabetes Mellitus
Milan Chag, MD
Percutaneous Coronary Intervention of Very Small Vessels in the RESOLUTE Global Clinical Program
Antonio Serra, MD
Patrick W. Serruys, MD
Randomized CTO-IVUS study
Yangsoo Jang, MD, PhD
ISAR-CLOSURE Randomized Trial
Stefanie Schupke , MD, et al.
P. Cervinka, MD, et al.
Axel Linke, MD , et al.
Two-Year Results From the CoreValve US Pivotal Trial
Steven J. Yakubov, MD
Katrin A. Fiedler, MD, et al.
SECURITY Randomized Clinical Trial
Antonio Colombo, MD
Yaling Han, MD
TRANSLATE-ACS Investigators
The IN.PACT Global Clinical Study
Gary M. Ansel, MD
1-year Results from the IN.PACT SFA II Trial
Adam C . Salisbury, MD, et al.
Serban Puricel, MD, et al.
I-LOVE-IT 2 Trial
Bo Xu, MD

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb